Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte announced completion of enrollment for all three OPUS Phase 3 trials for VAX-31, positioning the company for topline data readouts starting in Q4 2026 and a potential BLA submission. The company reported a strong cash position of $2.7 billion as of March 31, 2026, bolstered by net proceeds of $601.8 million from a February equity offering priced at $50.00 per share.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Drug Name
- VAX-31
- Revenue Yoy
- 0
- Deal Value Usd
- 632500000
- Phase Of Trial
- Phase 3
- Offering Price
- 50
- Shares Offered
- 12650000
- Net loss
- 320622000
- Ga expenses
- 33071000
- Rd expenses
- 312779000
- Cash position
- 2741195000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.